Bladder cancer stage 0 with carcinoma in situ represents the earliest form of bladder cancer, confined to the innermost lining of the bladder without spreading deeper into its walls. While this diagnosis might sound less severe, it requires careful attention because this type of cancer has unique characteristics that set it apart from other early bladder cancers.

What Is Stage 0 Bladder Cancer with Carcinoma in Situ?

Stage 0 bladder cancer refers to cancer cells found only in the tissue lining the inside of the bladder, without invading deeper into the bladder wall. This stage is divided into two distinct types based on how the cancer grows and appears. The term carcinoma in situ, often shortened to CIS, comes from Latin words meaning “in its original place,” indicating that the cancer hasn’t spread beyond where it first formed.^[2]

Stage 0is, or carcinoma in situ, appears as a flat tumor on the tissue lining the inside of the bladder. Unlike stage 0a (also called noninvasive papillary carcinoma), which may look like long, thin growths extending into the bladder lumen where urine collects, CIS spreads like a thin sheet along the surface of the urothelium (the innermost layer of bladder cells).^[2] This growth pattern makes CIS different from papillary carcinomas that grow inward toward the hollow part of the bladder in finger-like projections.^[5]

The bladder itself is a hollow, balloon-shaped organ in the lower part of the abdomen that stores urine. It has a muscular wall that allows it to expand to hold urine made by the kidneys and contract to squeeze urine out through the urethra. Understanding this anatomy helps explain why cancer confined to the inner lining is considered stage 0 – it hasn’t yet reached the muscle layers of the bladder.^[8]

Epidemiology

Between 75 and 80 percent of all bladder cancers are classified as non-muscle-invasive bladder cancer (NMIBC), meaning they haven’t spread to the muscle layer of the bladder. Among people diagnosed with NMIBC, approximately 10 percent have carcinoma in situ bladder cancer. Based on estimates from the American Cancer Society that almost 85,000 people in the United States will be diagnosed with bladder cancer in 2025, this means about 6,400 to 6,800 people in the U.S. are expected to receive a CIS diagnosis.^[5]

Stage 0 bladder cancer, including both papillary carcinoma and carcinoma in situ, represents the earliest stage of the disease that involves only the surface layer of the bladder. These cases are classified as superficial bladder cancers, though this term doesn’t diminish their importance or need for treatment.^[4]

Risk Factors

While the sources provided don’t detail specific risk factors for stage 0 bladder cancer with carcinoma in situ, understanding that this condition is a form of bladder cancer means it shares common risk factors with other bladder cancers. The development of cancer in the bladder lining occurs when cells begin to grow without normal control mechanisms, though the exact triggers for carcinoma in situ formation aren’t fully explained in the available information.

Symptoms

The symptoms of carcinoma in situ bladder cancer can vary depending on its size and location within the bladder. Even though CIS is an early-stage cancer, people with this diagnosis commonly experience bothersome and uncomfortable urinary symptoms that can significantly affect daily life.^[5]

The most common symptom of bladder cancer overall is hematuria, which means blood in the urine. Many people with early-stage bladder cancer notice blood in their urine without experiencing other uncomfortable symptoms. However, carcinoma in situ often presents differently.^[5]

Additional symptoms are usually more common in people with more advanced bladder cancer, but CIS can cause discomfort even at this early stage. This pattern of symptoms makes it important not to dismiss urinary changes as minor issues, especially when they persist or worsen over time.

Pathophysiology

Carcinoma in situ bladder cancer is always classified as high-grade, meaning the cancer cells look very abnormal compared to normal bladder cells when examined under a microscope. This grading system helps doctors understand how the cancer may progress and which treatments might work best.^[2][5]

The grade of bladder cancer differs from its stage. While stage describes how far cancer has spread, grade describes how abnormal the cells appear. Low-grade bladder cancer cells look more like normal bladder cells and tend to grow more slowly, often staying in the lining of the bladder. High-grade bladder cancer cells, like those in CIS, look very different from normal cells.^[5]

The cellular growth pattern of carcinoma in situ differs from that of papillary carcinoma, the other type of stage 0 bladder cancer. While papillary carcinomas grow outward into the bladder space, CIS remains flat against the bladder lining but spreads across its surface. This flat growth pattern, combined with the high-grade nature of the cells, means that CIS is more likely than papillary carcinoma to progress to invasive bladder cancer if left untreated.^[16]

The cancer begins in the urothelial cells, which are also called transitional cells because they have the ability to change shape. These specialized cells can stretch when the bladder fills with urine and shrink when it empties. In carcinoma in situ, these cells become cancerous but remain in their original location – the innermost layer of the bladder called the urothelium – without invading deeper tissues.^[5]

Treatment Approaches

The first treatment for carcinoma in situ is usually a surgical procedure called transurethral resection (TUR). During this operation, which serves both diagnostic and treatment purposes, a urologist inserts a thin, lighted tube called a cystoscope into the bladder through the urethra to examine the bladder lining. Through this tube, the doctor can remove tissue samples or remove the cancer visible in the bladder. The procedure also involves biopsy with electrical cautery or laser thermal destruction of all visualized cancer.^[4][16]

Because stage 0 bladder cancer, including carcinoma in situ, often returns after surgery, most people receive additional therapy. Treatment typically includes intravesical therapy, where medication is placed directly into the bladder. This may involve chemotherapy drugs like mitomycin or gemcitabine, or immunotherapy with BCG (Bacillus Calmette-Guérin), given around the time of the first surgery.^[9]

For carcinoma in situ, which is classified as high-risk bladder cancer, treatment typically includes TUR with fulguration followed by intravesical BCG therapy. Sometimes intravesical BCG continues for up to three years to lower the risk of recurrence, a strategy called maintenance therapy. The doctor may recommend continuing treatment based on the specific characteristics of the cancer.^[9][17]

If multiple tumors are present or if the cancer doesn’t respond to intravesical BCG therapy, another treatment option might be surgery to remove part or all of the bladder, a procedure called cystectomy. Radical cystectomy, involving complete removal of the bladder, may be considered in certain situations, though doctors carefully weigh the benefits against the impact on quality of life.^[9][16]

Surveillance and Follow-up

After treatment, regular surveillance becomes a crucial part of managing carcinoma in situ. Surveillance means closely watching the condition through frequent follow-up examinations performed at regular intervals to detect recurrent or new cancers before they become invasive. Routine surveillance tests include looking for cancer cells in the urine through a test called urinary cytology and direct visualization of the bladder lining through cystoscopy, typically performed every three months.^[4]

Surveillance with regular cystoscopies, where doctors inspect the bladder with a camera, and possibly additional imaging tests help monitor for signs of cancer recurrence or progression. The frequency and type of follow-up tests depend on the risk level assigned to the cancer and how it responded to initial treatment.^[9]

For people with carcinoma in situ, vigilant monitoring is essential because CIS has a higher chance of recurring or progressing to more advanced stages compared to other forms of stage 0 bladder cancer. This doesn’t mean treatment will fail, but it emphasizes the importance of maintaining scheduled follow-up appointments and promptly reporting any new symptoms to healthcare providers.^[5]